Kiniksa Pharmaceuticals, Ltd. (KNSA) P/E Ratio History
Historical price-to-earnings valuation from 2022 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 1, 2026, Kiniksa Pharmaceuticals, Ltd. (KNSA) trades at a price-to-earnings ratio of 59.3x, with a stock price of $44.49 and trailing twelve-month earnings per share of $1.50.
The current P/E is 53% below its 5-year average of 125.6x. Over the past five years, KNSA's P/E has ranged from a low of 3.9x to a high of 691.8x, placing the current valuation at the 56th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, KNSA trades at a 150% premium to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, KNSA commands a significant premium over the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our KNSA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Immunology and Inflammation Therapies peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
ARGXargenx SE | $47B | 60.0 | -Best | +348% |
TGTXTG Therapeutics, Inc. | $5B | 200.6 | -Best | +76% |
KNSAKiniksa Pharmaceuticals, Ltd. | $3B | 59.3 | -Best | +225% |
APLSApellis Pharmaceuticals, Inc. | $3B | 116.4 | -Best | +111% |
GLPGGalapagos N.V. | $2B | 5.9Lowest | -Best | +333% |
AUPHAurinia Pharmaceuticals Inc. | $2B | 6.8 | -Best | +5167%Best |
GYREGyre Therapeutics, Inc. | $711M | 164.8 | -Best | +104% |
RIGLRigel Pharmaceuticals, Inc. | $615M | 35.1 | -Best | +169% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $41.25 | $0.75 | 55.0x | -56% |
| FY2025 Q3 | $38.83 | $0.45 | 86.3x | -31% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $27.67 | $0.04 | 691.8x | +451% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $19.73 | $0.11 | 179.4x | +43% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $17.54 | $0.18 | 97.4x | -22% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $14.08 | $3.27 | 4.3x | -97% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $10.76 | $2.77 | 3.9x | -97% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $14.98 | $2.59 | 5.8x | -95% |
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $12.84 | $2.00 | 6.4x | -95% |
Average P/E for displayed period: 125.6x
See KNSA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KNSA Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare KNSA vs AGIO
See how KNSA stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is KNSA stock overvalued or undervalued?
KNSA trades at 59.3x P/E, below its 5-year average of 125.6x. At the 56th percentile of historical range, the stock is priced at a discount to its own history.
How does KNSA's valuation compare to peers?
Kiniksa Pharmaceuticals, Ltd. P/E of 59.3x compares to sector median of 23.7x. The premium reflects expected growth above peers.
What is KNSA's PEG ratio?
KNSA PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2022-2025.